313 related articles for article (PubMed ID: 17383932)
21. Do angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers decrease the risk of hospitalization secondary to community-acquired pneumonia? A nested case-control study.
Etminan M; Zhang B; Fitzgerald M; Brophy JM
Pharmacotherapy; 2006 Apr; 26(4):479-82. PubMed ID: 16553505
[TBL] [Abstract][Full Text] [Related]
22. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials.
Tokmakova M; Solomon SD
Curr Opin Cardiol; 2006 Jul; 21(4):268-72. PubMed ID: 16755193
[TBL] [Abstract][Full Text] [Related]
23. Therapy with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins: no effect on ablation outcome after ablation of atrial fibrillation.
Richter B; Derntl M; Marx M; Lercher P; Gössinger HD
Am Heart J; 2007 Jan; 153(1):113-9. PubMed ID: 17174648
[TBL] [Abstract][Full Text] [Related]
24. Design of the heart failure endpoint evaluation of AII-antagonist losartan (HEAAL) study in patients intolerant to ACE-inhibitor.
Konstam MA; Poole-Wilson PA; Dickstein K; Drexler H; Justice SJ; Komajda M; Malbecq W; Martinez FA; Neaton JD; Riegger GA; Guptha S
Eur J Heart Fail; 2008 Sep; 10(9):899-906. PubMed ID: 18768350
[TBL] [Abstract][Full Text] [Related]
25. Pharmacotherapy according to treatment guidelines is associated with lower mortality in a community-based sample of patients with chronic heart failure: a prospective cohort study.
Störk S; Hense HW; Zentgraf C; Uebelacker I; Jahns R; Ertl G; Angermann CE
Eur J Heart Fail; 2008 Dec; 10(12):1236-45. PubMed ID: 18996739
[TBL] [Abstract][Full Text] [Related]
26. Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes.
Winkelmayer WC; Fischer MA; Schneeweiss S; Wang PS; Levin R; Avorn J
Am J Kidney Dis; 2005 Dec; 46(6):1080-7. PubMed ID: 16310574
[TBL] [Abstract][Full Text] [Related]
27. How should we manage heart failure developing in patients already treated with angiotensin-converting enzyme inhibitors and beta-blockers for hypertension, diabetes or coronary disease?
Gustafsson F; Segura J; Ruilope LM
J Hypertens; 2010 Aug; 28(8):1595-8. PubMed ID: 20613629
[TBL] [Abstract][Full Text] [Related]
28. Have angiotensin receptor blockers lived up to expectations?
Fitchett D
Can J Cardiol; 2005 May; 21(7):569-75. PubMed ID: 15940354
[TBL] [Abstract][Full Text] [Related]
29. Angiotensin-converting enzyme inhibitors prescription is associated with longer survival among patients hospitalized for congestive heart failure who have preserved systolic function: a long-term follow-up study.
Grigorian Shamagian L; Roman AV; Ramos PM; Veloso PR; Bandin Dieguez MA; Gonzalez-Juanatey JR
J Card Fail; 2006 Mar; 12(2):128-33. PubMed ID: 16520261
[TBL] [Abstract][Full Text] [Related]
30. [Pharmacologic treatment of heart failure in the elderly].
Erdmann E
Dtsch Med Wochenschr; 2013 Apr; 138(14):700-2. PubMed ID: 23533033
[No Abstract] [Full Text] [Related]
31. Effect of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on the rate of new-onset diabetes mellitus: a review and pooled analysis.
McCall KL; Craddock D; Edwards K
Pharmacotherapy; 2006 Sep; 26(9):1297-306. PubMed ID: 16945052
[TBL] [Abstract][Full Text] [Related]
32. Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers.
Raebel MA; McClure DL; Simon SR; Chan KA; Feldstein A; Andrade SE; Lafata JE; Roblin D; Davis RL; Gunter MJ; Platt R
Pharmacoepidemiol Drug Saf; 2007 Jan; 16(1):55-64. PubMed ID: 16470693
[TBL] [Abstract][Full Text] [Related]
33. National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction.
Masoudi FA; Rathore SS; Wang Y; Havranek EP; Curtis JP; Foody JM; Krumholz HM
Circulation; 2004 Aug; 110(6):724-31. PubMed ID: 15289383
[TBL] [Abstract][Full Text] [Related]
34. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact.
Jorde UP
Cardiol Rev; 2006; 14(2):81-7. PubMed ID: 16493245
[TBL] [Abstract][Full Text] [Related]
35. Valsartan in chronic heart failure.
Ripley TL
Ann Pharmacother; 2005 Mar; 39(3):460-9. PubMed ID: 15687480
[TBL] [Abstract][Full Text] [Related]
36. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
Vijan SG
J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
[TBL] [Abstract][Full Text] [Related]
37. Patterns of physician use of angiotensin converting enzyme inhibitors in the inpatient treatment of congestive heart failure.
Ghali JK; Giles T; Gonzales M; Horswell R; Kumar S; Lejuene A; Livaudais GF; Sarkar IC
J La State Med Soc; 1997 Dec; 149(12):474-84. PubMed ID: 9425858
[TBL] [Abstract][Full Text] [Related]
38. Left ventricular diastolic heart failure with normal left ventricular systolic function in older persons.
Aronow WS
J Lab Clin Med; 2001 May; 137(5):316-23. PubMed ID: 11329528
[TBL] [Abstract][Full Text] [Related]
39. Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure.
McNamara DM; Holubkov R; Postava L; Janosko K; MacGowan GA; Mathier M; Murali S; Feldman AM; London B
J Am Coll Cardiol; 2004 Nov; 44(10):2019-26. PubMed ID: 15542286
[TBL] [Abstract][Full Text] [Related]
40. [Temporal trends in pharmacological therapy in the IN-CHF registry from 1995 to 2005].
Fabbri G; Gorini M; Maggioni AP; Di Lenarda A;
G Ital Cardiol (Rome); 2007 Feb; 8(2):102-6. PubMed ID: 17402354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
